was collected for analysis. Results: CBD 50 mg/kg ( n = 4) induced significant hypotension in 2 out of 4 piglets, and 1 out of 4 piglets suffered a fatal cardiac arrest. CBD 25 mg/kg ( n = 4) induced significant hypotension in 1 out of 4 piglets, while 10 mg/kg ( n = 5) was well tolerated. A significant negative correlation between the plasma concentration of CBD and hypotension during drug infusion was observed ( p < 0.005). Neuroprotective effects were evaluated in piglets that did not display significant hypotension ( n = 9) and CBD did not alter the degree of neuronal damage as measured by a neuropathology score, levels of the astrocytic marker S100B in CSF, magnetic resonance spectroscopy markers (Lac/NAA and Glu/NAA ratios), or plasma troponin T. Conclusions: High-dose CBD can induce severe hypotension and did not offer neuroprotection in the early phase after global HI in piglets.
mic encephalopathy [1] [2] [3] [4] [5] [6] and has received orphan designation status for this condition [7] .
Neuroprotection by CBD after perinatal hypoxia-ischemia (HI) has been demonstrated after doses ranging from 0.1 to 1,000 μmol/L in whole brain slices from mice [8] , 1 to 30 mg/kg intraperitoneally in rats [9] , and 0.1 to 1 mg/kg i.v. in piglets [3] [4] [5] . We recently studied the effects of CBD 1 mg/kg i.v. in a piglet model of global HI [10] , and in contrast to previous studies in piglets [2] [3] [4] [5] no neuroprotective effects were found in the early phase after HI. The hypoxic-ischemic insult in our model produces more severe multiorgan damage compared to these studies [2] [3] [4] [5] . As the effects of cannabinoids have been shown to depend both on the dose and pathophysiological setting [11, 12] , we hypothesized that higher doses of CBD could be required to demonstrate efficacy in this animal model.
However, when considering high-dose CBD in this setting it is important to be aware of its possible effects on other organs, like the cardiovascular system, where CBD's actions on the heart and vasculature have been demonstrated in several in vitro studies [12] [13] [14] [15] . Even though intravenous CBD up to 100 mg/kg in animal models [16] and 30 mg/kg in humans [16, 17] have been well tolerated, these studies did not involve global HI, which is known to induce cardiovascular dysfunction [18] . In piglets exposed to HI, the highest dose of CBD yet to be tested is 1 mg/kg i.v., and it did not produce unwanted cardiovascular effects [3, 4, 10] .
Hence the aim of this study was to evaluate the safety of high-dose CBD (>10 mg/kg) after global HI in piglets, and further to perform a preliminary assessment of possible neuroprotective effects.
Materials and Methods

Approval
The Norwegian Council for Animal Research approved the experimental protocol (approval No. 7359). The animals were cared for and handled in accordance with the European Guidelines for Use of Experimental Animals, by certified FELASA (Federation of European Laboratory Animals Science Associations) Category C researchers.
Experimental Protocol
The animal model used has been extensively described previously [10] . Briefly, 22 newborn Noroc (LyxLD) pigs were exposed to HI by ventilation with a gas mixture of 8% O 2 in N 2 until either the mean arterial blood pressure (MABP) decreased to 20 mm Hg or the base excess reached − 20 mmol/L. After resuscitation, the piglets were randomized, by sealed envelopes, to treatment with high-dose CBD ( n = 13) or vehicle (VEH) ( n = 9). We have previously demonstrated a significant effect of HI on the parameters assessed in this study [10] and thus a nonhypoxic control group was not included in the current experiments.
The MABP was measured continuously in the left carotid artery using BioPac Systems MP150-CE (Goleta, CA, USA). The O 2 saturation was monitored by pulse oximetry (Masimo RAD-5 Pulse Oximeter; Neuchatel, Switzerland). Rectal temperature was measured by a digital rectal thermometer and maintained between 38.5 and 40.0 ° C. Temperature-corrected arterial acid/ base status, glucose, and hemoglobin were regularly measured on a Blood Gas Analyzer 860 (Ciba Corning Diagnostics, Midfield, MA, USA). Apart from during the hypoxic insult, mechanical ventilation settings were adjusted to maintain normoventilation.
Blood and CSF for analysis were obtained at the end of the experiment (9.5 h after HI). Samples were immediately snap-frozen in liquid nitrogen and stored at -80 ° C. The animals were euthanized with an overdose of pentobarbital (150 mg/kg i.v.). The brain was immediately removed and sagitally divided. From the right half, specimens from the frontoparietal cortex and the hippocampus were snap-frozen in liquid nitrogen and stored at − 80 ° C until subsequent analysis. The left hemisphere was placed in 4% buffered formalin for subsequent histopathological analysis.
Dose and Administration of Cannabidiol
A starting dose of CBD 50 mg/kg (GW Research Ltd., Cambridge, UK) was chosen based on the existing literature [16] . If significant side effects occurred, the dose was to be reduced stepwise to 25, 10, and 5 mg/kg. The side effects evaluated were severe hypotension, defined as a drop in blood pressure to <70% of baseline MABP (start infusion).
CBD was prepared in a 10 mg/mL formulation of ethanol: solutol:saline at a ratio of 2: 1:17. CBD was mixed with saline to give a total volume of 20 mL. VEH-treated animals received an equivalent amount of VEH to the CBD 50 mg/kg dose regimen. CBD and VEH were given 30 min after the end of hypoxia intravenously over 15 min.
Plasma and Brain Concentrations CBD
Plasma and brain levels of CBD were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) at LGC (Fordham, UK).
Histology
A transcoronal block ( ∼ 0.4 cm thick) from the level of the parietal cortex including the basal ganglia was prepared, processed in a Leica TP1050 tissue processor (GMI, Anoka, MN, USA), embedded in paraffin, sliced in 4-μm-thick sections, and stained with hematoxylin and eosin.
Analysis was performed by an experienced pathologist blinded to the randomization/clinical details. Areas with vacuolated neuropil, shrunken neurons with pyknotic nuclei, and scattered eosinophilic neurons were defined as early neuronal damage. A modified version of a validated scoring system [19] was used. Based on evaluation of the whole brain section, including the cortex, white matter, and basal ganglia, a global score ranging from 0 to 4 was given to each piglet: 0 = no damage and 4 = massive damage with autolysis of the brain. Biomarkers S100B in CSF and plasma troponin T were measured using electrochemiluminescent immunometric assay on the Cobas e601 immunoassay platform (Roche Diagnostics, Mannheim, Germany).
Ex vivo Proton Magnetic Resonance Spectroscopy (H + -MRS) H
+ -MRS was performed by the collaborative unit in Madrid in the MRI Unit of the Instituto Pluridisciplinar (Universidad Complutense, Madrid, Spain) and the method is extensively described in the papers by Pazos et al. [4] and Lafuente et al. [3] . 
Results
Cohort Description
Twenty-two piglets were included in the study (VEH = 9 and CBD = 13). No significant differences in baseline physical variables or biophysical and biochemical variables were observed between the study groups ( Table 1 ) .
Plasma and Brain Concentrations
The plasma and brain concentrations of CBD showed a linear relationship with dose ( Fig. 1 ) . CBD levels in the brain were strongly correlated with plasma levels (β = 0.4 μg [95% CI 0.3-0.5], p < 0.0001) ( Fig. 1 c) .
Safety
There were no significant group differences in hemodynamic variables before treatment ( Table 1 ) . No significant difference in heart rate was observed during treatment ( Table 1 ) . Three of the 4 piglets in the CBD 50 mg/kg group displayed significant hypotension, with a drop in MABP below 70% of baseline. One of these One of the 4 piglets receiving 25 mg/kg displayed severe hypotension, but the group mean drop was not significant (CBD 25 mg/kg -8 ± 10 mm Hg vs. VEH -2 ± 4 mm Hg, p = 0.29). VEH and CBD 10 mg/kg did not produce significant hypotension. We observed a significant negative association between the plasma concentration of CBD at 3 h after the dose and MABP with a mean drop of -1 mm Hg (95% CI -1.7 to -0.5, p = 0.002) per 1-μg increase in CBD ( Fig. 3 b) .
Neuroprotection
The neuropathology score was not significantly different in piglets receiving high-dose CBD compared to VEH (CBD score 1.9 ± 1.4 vs. VEH 1.6 ± 1.3, p = 0.67), and CBD did not significantly alter the levels of S100B in cerebrospinal fluid (CBD 17.8 ± 11.9 vs. VEH 11.5 ± 11.9 ng/mL, p = 0. Table 2 ).
The above analysis included all animals receiving highdose CBD ( n = 9) or VEH ( n = 9), except piglets who displayed severe hypotension during treatment ( n = 4). Subgroup analysis of the individual doses of CBD had, prior to this, not shown significant differences between groups.
Discussion
In this study we evaluated the safety of high-dose CBD in newborn piglets exposed to global HI as well as performed a preliminary assessment of efficacy. We have demonstrated that high-dose CBD in this setting can induce severe hypotension in some animals. Further, highdose CBD did not offer neuroprotection in the first 9.5 h after HI as evaluated by a neuropathology score, levels of the astrocytic marker S100B in cerebrospinal fluid, hippocampal proton magnetic resonance spectroscopy biomarkers, or plasma troponin T levels.
CBD has been shown to induce hypotension in animals previously [12] , but in most studies even high doses have been well tolerated [16] . However, these models did not induce severe global HI. Cardiovascular dysfunction in the current animal model is demonstrated by severe hypotension during HI, and in the recovery phase a degree of persistent hypotension and tachycardia, as well as significantly elevated plasma troponin T [10] . High-dose CBD did not induce cardiac arrhythmias or significant alterations in heart rate. Still, in this setting, with a compromised myocardial function [18] , CBD's vasorelaxant effects [14, 20] and its ability to depress the contractility of myocytes [15] and to reduce the cardiovascular response to stress [13] can all be potential explanations for the observed hypotension. A significant correlation between the plasma concentrations of CBD and the degree of hypotension during infusion was observed. All piglets displaying a significant drop in MABP had plasma levels of CBD above 4 μg/mL at 3 h after the dose. This corresponds to an estimated molar concentration of approximately 13 μmol/L. The initial concentrations, however, are likely far greater as C max after intravenous administration is achieved almost instantaneously. In an in vitro study on the preconstricted rat aorta, CBD 5-10 μmol/L were found to induce a 25-50% relaxation, respectively, [20] and in another in vitro study on rat myocytes, CBD as low as 1 μmol/L was found to exert negative inotropic effects [15] . We should, however, be cautious when extrapolating the effects of in vitro concentrations to in vivo studies [21] . Modifications in the method of CBD administration, e.g., by using a slower infusion rate or giving CBD later when cardiovascular function has improved, could have limited the observed effects, and we did not treat hypotension with vasopressors or inotropic drugs. Regardless, the possibility of inducing unwanted hypotension is a possible limitation of the highest doses of CBD in this setting.
We found no significant protective effects of high-dose CBD on the levels of early neuronal damage assessed by neuropathology. CBD also did not alter the levels of S100B in cerebrospinal fluid or plasma troponin T, both of which have been found to predict outcome after perinatal HI [18, 22] . Proton magnetic spectroscopy biomarkers, especially the Lac/NAA ratio, are early predictors of outcome after neonatal HI [23] , but were not influenced by high-dose CBD in our study. Although we have evaluated a limited number of variables, they have all been used previously to demonstrate CBD's neuroprotective effects in piglets [3] [4] [5] . Explanations for the absence of neuroprotection in our model compared to previous studies in piglets [2] [3] [4] [5] have been thoroughly discussed before [10] . Most relevant is probably the difference in the nature of HI. Among others, the duration of HI is longer in our model (40-55 vs. 20-30 min) and piglets have a more profound metabolic acidosis (pH 6.85 vs. 7.2).
In regard to neuroprotection, an important limitation of this study is the short survival time, as it allows us only to study effects limited to the latent phase and early secondary energy failure after perinatal HI [24] . Nevertheless, the majority of the existing literature in support of CBD's neuroprotective effects after neonatal HI have used comparable endpoints (6 h) [2] [3] [4] . As such, the evidence of CBD's full potential after perinatal HI is still limited and difficult to interpret. Further, we acknowledge the relatively small sample size and the variation in degree of injury after HI seen in this model. The animals excluded due to severe hypotension did not display significant differences in the outcome variables related to neuroprotection, and including them would not have altered the overall results. Nevertheless, we found it most appropriate to exclude them based on the probability of brain ischemia caused by such a severe drop in MABP which is considered to be below the lower limit of cerebral autoregulation in piglets [25] .
Before considering clinical trials with CBD in the setting of perinatal HI, it is, in our opinion, necessary to confirm its safety and efficacy in different preclinical models. In this regard our study is highly relevant. Although adverse effects were seen only after the highest doses, and might be prevented by modifications in the timing and method of administration, they are important to consider in future studies. In the current animal model CBD failed to demonstrate neuroprotective effects; however, its full neuroprotective potential and optimal dose remain to be determined.
